- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04003233
Limited-efficacy Testing of Spring Distraction System (SDS) and Unilateral One-way Rod (MID-C) for Early Onset Scoliosis (UniPOWR)
Study Overview
Status
Intervention / Treatment
Detailed Description
Rationale: EOS is a severe and potentially life-threatening disorder since a disturbance of spinal development leads to impaired development of the trunk, with cardio-respiratory failure as a result, often early in adult life. Several innovative solutions have been developed to treat growing children with severe EOS. The SDS device was developed internally at the dpt. of orthopedics at the UMC Utrecht, the Netherlands, the MID-C device was developed by the company ApiFix Ltd.
Objective: The primary aim of this study is to investigate the limited efficacy of these innovative surgical solutions in treatment of early onset scoliosis in terms of maintaining reduction while maintaining spinal growth. The secondary aim is to compare both devices for these and other parameters as well as safety.
Study design: A feasibility study using two prospective cohorts according to an open label randomized clinical trial (RCT) design. The study will be done in two tertiary referral centers (UMC Utrecht and Amsterdam UMC). Primary endpoints are maintenance of curve correction as well as complications. These data will be compared to a recently described cohort of patients that received a "standard treatment" (Magnetically controlled growing rod (MCGR)). The same endpoints as well as secondary outcomes, will be compared between the two new treatments.
Study population: Children with idiopathic(-like) early onset scoliosis with an indication for a growing rod implant.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Utrecht, Netherlands, 3584 CX
- UMC Utrecht
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1105 AZ
- Amsterdam UMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ambulant skeletally immature children, 6-12 yrs. of age, with open triradiate cartilages on X-ray
- Scoliosis diagnosis prior to the age 10
- Diagnosis of idiopathic or mild syndromic scoliosis (e.g. 22q11DS, Trisomy 21 or 9, Coffin-Siris)
- Progressive scoliosis qualified for growth system surgery
- One curve for treatment with an apex below Th5 and a proximal end vertebra below Th2
- The primary curve must be between 35 and 75 degrees coronal Cobb angle
- The primary curve must be non-rigid (i.e. the curve reduces on bending X-rays to <35 degrees or reduces >30% )
- Normal or hypokyphotic sagittal alignment (Th5 -Th12 < 50 degrees) on lateral X-rays
Exclusion Criteria:
- Patients with an obvious neuromuscular disease
- Patients that are severely mentally retarded
- Patients with a scoliosis that extends to the pelvis or the cervicothoracic region
- Patients with a main curve of more than 8 vertebra Cobb to Cobb
- Patients with a skeletal dysplasia that effects growth (e.g. achondroplasia, SED)
- Patients with a systemic disease which severely influences bone quality (e.g. osteogenesis imperfecta, metabolic diseases)
- Patients with soft tissue weakness (e.g. Ehler Danlos, Marfan, Neurofibromatosis, Prader Willi)
- Patients with an active systemic disease such as Juvenile Idiopathic Arthritis, HIV or oncologic treatment
- Patients with a previous surgical fusion of the spine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Spring Distraction System
The SDS device will be implanted during a scoliosis correction operation.
|
The SDS will be added to a traditional growing rod (TGR) of 4.5 or 5.5mm.
|
|
Experimental: Minimal Invasive Deformity Correction system
The MID-C device will be implanted during a scoliosis correction operation.
|
The MID-C system consists of a unilateral one-way ratchet rod that is connected to the spine with polyaxial connectors
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Limited-efficacy of SDS and MID-C in terms of curve correction maintenance: changes in cobb angle
Time Frame: Until 1 year post-operative FU
|
changes in cobb angle on radiographs post-op and at 4 weeks, 3 months and 12 months follow-up (FU).
A maximum of 5 degrees increase will be the threshold to define maintenance.
|
Until 1 year post-operative FU
|
|
Incidence of Treatment-Emergent Serious Adverse Events of SDS and MID-C
Time Frame: Until 1 year post-operative FU
|
Reported treatment related Serious Adverse Events (SAEs) per-operatively and at 4 weeks, 3 months and 12 months FU.
|
Until 1 year post-operative FU
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Limited-efficacy of SDS and MID-C in terms of spinal length
Time Frame: Until 1 year post-operative FU
|
Changes in length of T1-T12, T1-S1 and the instrumented segment in mm on calibrated Anterior Posterior (AP) X-rays post-op and at 4 weeks, 3 months and 12 months FU.
|
Until 1 year post-operative FU
|
|
SDS vs. MID-C with respect to limited-efficacy in terms of curve correction maintenance
Time Frame: Until 1 year post-operative FU
|
changes in cobb angle on radiographs post-op and at 4 weeks, 3 months and 12 months FU.
A maximum of 5 degrees increase will be the threshold to define maintenance.
|
Until 1 year post-operative FU
|
|
SDS vs. MID-C with respect to limited-efficacy in terms of spinal length
Time Frame: Until 1 year post-operative FU
|
Changes in length of T1-T12, T1-S1 and the instrumented segment in mm on calibrated AP X-rays post-op and at 4 weeks, 3 months and 12 months FU.
|
Until 1 year post-operative FU
|
|
SDS vs. MID-C with respect to the incidence of Treatment-Emergent Serious Adverse Events
Time Frame: Until 1 year post-operative FU
|
Reported treatment related SAEs per-operatively and at 4 weeks, 3 months and 12 months FU.
|
Until 1 year post-operative FU
|
|
SDS vs. MID-C with respect to surgery time
Time Frame: Until 1 year post-operative FU
|
Surgery time in minutes
|
Until 1 year post-operative FU
|
|
SDS vs. MID-C with respect to blood loss during surgery
Time Frame: Until 1 year post-operative FU
|
blood loss in cc
|
Until 1 year post-operative FU
|
|
SDS vs. MID-C with respect to length of hospital stay
Time Frame: Until 1 year post-operative FU
|
length of hospital stay in days
|
Until 1 year post-operative FU
|
|
SDS vs. MID-C with respect to recovery time
Time Frame: Until 1 year post-operative FU
|
recovery time in minutes
|
Until 1 year post-operative FU
|
|
SDS vs. MID-C with respect to bone density
Time Frame: Until 1 year post-operative FU
|
Bone density changes of the bypassed vertebrae on Dual Energy X-ray Absorptiometry (DEXA)scan post-op and at 3 months en 12 months FU.
|
Until 1 year post-operative FU
|
|
SDS vs. MID-C with respect to Quality Of Life (QOL) on the Early Onset Scoliosis Questionnaires (EOSQ-24)
Time Frame: Until 1 year post-operative FU
|
Parent reported QOL and performance is assessed with the 24-item Early Onset Scoliosis Questionnaires (EOSQ-24) pre-op and at 4 weeks, 3 months and 12 months FU.
EOSQ-24 covers the following domains: Child's Health Related Quality of Life (16 items), Family Impact (2 items) and Satisfaction (2 items).
|
Until 1 year post-operative FU
|
|
SDS vs. MID-C with respect to flexibility of the spine
Time Frame: Until 1 year post-operative FU
|
Flexibility and 3D rotation of the spine on dynamic echography (Scolioscan)
|
Until 1 year post-operative FU
|
|
SDS vs. MID-C with respect to 3D development of the spine
Time Frame: Until 1 year post-operative FU
|
Apical Vertebral Rotation based on MRI
|
Until 1 year post-operative FU
|
|
SDS vs. MID-C with respect to patient appearance
Time Frame: Until 1 year post-operative FU
|
sagittal balance on clinical photographs post-op and at 1 year FU
|
Until 1 year post-operative FU
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Moyo C Kruyt, MD, PhD, UMC Utrecht
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL63511.041.17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Scoliosis
-
National Scoliosis CenterCompletedAdolescent Idiopathic Scoliosis (AIS) | Neuromuscular Scoliosis | Juvenile Idiopathic Scoliosis | Infantile Idiopathic Scoliosis | Ealy Onset ScoliosisUnited States
-
Lahore University of Biological and Applied SciencesGhurki Trust and Teaching HospitalNot yet recruitingScoliosis Idiopathic | Idiopathic Adolescent ScoliosisPakistan
-
Uppsala UniversityUniversity of Oslo; Linkoeping University; Örebro University, Sweden; Skane University... and other collaboratorsNot yet recruitingIdiopathic Adolescent Scoliosis | Idiopathic Juvenile ScoliosisSweden
-
Hasan Kalyoncu UniversityNot yet recruitingScoliosis Idiopathic | Scoliosis Idiopathic Adolescent | Caregiver AnxietyTurkey (Türkiye)
-
Cairo UniversityRecruitingScoliosis Idiopathic | Adolescent Idiopathic ScoliosisEgypt
-
Istinye UniversityRecruitingScoliosis Idiopathic Adolescent Treatment | Scoliosis Idiopathic AdolescentTurkey (Türkiye)
-
Medtronic Spinal and BiologicsMedical Metrics Diagnostics, IncTerminatedAdolescent Idiopathic Scoliosis | Juvenile Idiopathic ScoliosisUnited States, Canada, United Kingdom
-
Dr. Casey Stondell, MDPacira Pharmaceuticals, IncCompletedAdolescent Idiopathic Scoliosis | Juvenile Idiopathic ScoliosisUnited States
-
Spino Modulation Inc.TerminatedAdolescent Idiopathic Scoliosis | Juvenile Idiopathic ScoliosisCanada
-
Istituto Scientifico Italiano Colonna VertebraleActive, not recruitingAdolescent Idiopathic Scoliosis (AIS) | Juvenile Idiopathic ScoliosisItaly
Clinical Trials on SDS
-
VisCardia Inc.Clinical AcceleratorCompletedHeart Failure With Reduced Ejection FractionGeorgia, Uzbekistan
-
Mondelēz International, Inc.University of SydneyCompletedMetabolism and Nutrition DisordersAustralia
-
UMC UtrechtEUROSCompletedNeuromuscular Scoliosis | Distraction System | Growth Friendly SystemNetherlands
-
VisCardia Inc.Duke Clinical Research Institute; Clinical AcceleratorRecruitingHeart Failure With Reduced Ejection FractionUnited States
-
Mondelēz International, Inc.University of SydneyCompletedMetabolic Disorder; Carbohydrate, Absorption, IntestineAustralia
-
University of GiessenRecruiting
-
Edinburgh Biosciences LtdMDX ResearchCompletedAge-related CataractLatvia, Lithuania, Romania
-
Mondelēz International, Inc.Centre de Recherche en Nutrition Humaine Rhone-Alpe; Biofortis Mérieux NutriSciencesCompleted
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedOvarian CancerUnited States
-
Cordis CorporationCompletedCoronary Artery DiseaseUnited States